Menu
Your search for “ ���� Cattle Ivermectin ���� www.Ivermectin-Stromectol.com ���� Guinea Pig Mites Ivermectin ���� Oral Ivermectin , Ivermectin Pi” returned the following results.
…opposed to a conventional food (e.g., fruits, vegetables, fats, sugars, etc.) that – in its natural state – happens to provide high (or low) amounts of a required nutrient. Comments…
…for Stay (Docket No. FDA-2013-P-0119), Ferring Pharmaceuticals, Inc. (“Ferring”) requestes that FDA reconsider its denial of NCE exclusivity for PREPOPIK (sodium picosulfate, magnesium oxide and citric acid) for Oral Solution. …
…to file supplemental briefs by April 21, 2014 addressing “[w]hether, under the First Amendment, judicial review of mandatory disclosure of ‘purely factual and uncontroversial’ commercial information, compelled for reasons other…
…NCE exclusivity for approved FDCs containing an NCE and a previously-approved drug – specifically STRIBILD (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) Tablets (Docket No. FDA-2013-P-0058); PREPOPIK (sodium picosulfate, magnesium oxide…
…compounded drugs only when they are prepared in compliance with the Federal Food, Drug, and Cosmetic Act. The Drug Quality and Security Act, which was enacted on November 27, 2013,…
…claims but claims (direct and indirect) that POM products fought specific diseases, i.e., atherosclerosis, prostate cancer, and erectile dysfunction. According to the FTC, the Court may rely on and should…
…due on October 23, 2013. Although oral arguments have not yet been scheduled, Appellants requested scheduling as soon as possible after they file their reply brief, due Nov. 1, 2013…
…Kingdom, and (B) pharmacies located in countries other than Canada, the United Kingdom, Australia, or New Zealand. Plaintiffs’ own alleged injuries from the 2013 Amendment are indirect, remote, and speculative….
…of Appeals for the D.C. Circuit (see our previous posts here and here). Following several extensions for filing its opening brief, on August 14, 2013, POM Wonderful LLC Roll Global,…
…STRIBILD (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) Tablets (Docket No. FDA-2013-P-0058), which FDA approved on August 27, 2012 under NDA No. 203100 and for which the Agency has not yet…
…an element of strength for certain products (e.g., parenteral solutions) but is not typically broken out for others (e.g., solid oral dosage forms),” which, FDA posits, suggests “that the terms…
…the settlement.” To make a more-apples-to-apples comparison, the IMS then uses the FTC’s estimate (from the March 25, 2013 Oral Argument in Federal Trade Commission v. Actavis) that approximately 26%-30%…
…remedy Judge Korman ordered is erroneous for (at least) two reasons: First, the Court exceeded its authority by issuing an order concerning the “one-pill product,” i.e., Plan B One-Step (PBOS),…
…drugs and biologics by authorizing the Federal Trade Commission to stop companies from entering into anti-competitive deals, known also as “pay for delay” agreements, intended to block consumer access to…
…in these prior blogposts, rescheduling hydrocodone products from Schedule III to Schedule II would affect popular hydrocodone combination products such as Vicodin, Lortab, Lorcet, Norco, Hycodan and Vicoprofen. (However, bulk…